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A Randomized, Controlled, Phase 2 
Study of Maralixibat in the Treatment of 
Itching Associated With Primary Biliary 
Cholangitis
Marlyn J. Mayo,1 Paul J. Pockros,2 David Jones,3 Christopher L. Bowlus ,4 Cynthia Levy,5 Imran Patanwala,6 Bruce Bacon,7 
Velimir Luketic,8,9 Raj Vuppalanchi,10 Sharon Medendorp,11 Alejandro Dorenbaum,12 Ciara Kennedy,13 Patricia Novak,14 Joan Gu,15 
George Apostol,16 and Gideon M. Hirschfield17
Primary biliary cholangitis (PBC) is typically associated with elevated serum bile acid levels and pruritus, but pru-
ritus is often refractory to treatment with existing therapies. This phase 2 study assessed the efficacy and safety of 
maralixibat, a selective, ileal, apical, sodium-dependent, bile acid transporter inhibitor, in adults with PBC and pru-
ritus. Adults with PBC and pruritus who had received ursodeoxycholic acid (UDCA) for ≥6 months or were intoler-
ant to UDCA were randomized 2:1 to maralixibat (10 or 20 mg/day) or placebo for 13 weeks in combination with 
UDCA (when tolerated). The primary outcome was change in Adult Itch Reported Outcome (ItchRO™) average 
weekly sum score (0, no itching; 70, maximum itching) from baseline to week 13/early termination (ET). The study 
enrolled 66 patients (maralixibat [both doses combined], n = 42; placebo, n = 24). Mean ItchRO™ weekly sum scores 
decreased from baseline to week 13/ET with maralixibat (–26.5; 95% confidence interval [CI], –31.8, –21.2) and 
placebo (–23.4; 95% CI, –30.3, –16.4). The difference between groups was not significant (P = 0.48). In the mara-
lixibat and placebo groups, adverse events (AEs) were reported in 97.6% and 70.8% of patients, respectively. 
Gastrointestinal disorders were the most frequently reported AEs (maralixibat, 78.6%; placebo, 50.0%). Conclusion: 
Reductions in pruritus did not differ significantly between maralixibat and placebo. However, a large placebo effect 
may have confounded assessment of pruritus. Lessons learned from this rigorously designed and executed trial are 
indispensable for understanding how to approach trials assessing pruritus as the primary endpoint and the therapeu-
tic window of bile acid uptake inhibition as a therapeutic strategy in PBC. (Hepatology Communications 
2019;3:365-381).
Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis,(1) is a rare, chronic, progressive, autoimmune, cholestatic liver disease characterized by damage to intrahepatic bile ducts. Pruritus is a common clinical symptom of PBC, reported to affect 20%-75% of individuals,(2) 
Abbreviations: AE, adverse event; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; C4, 
7α-hydroxy-4-cholesten-3-one; CI, confidence interval; ET, early termination; FGF, fibroblast growth factor; GGT, gamma-glutamyl transferase; 
IBAT, ileal bile acid transporter; ItchRO™, Itch Reported Outcome; ITT, intent-to-treat; LDL-C, low-density lipoprotein cholesterol; LS, least 
squares; MOS-Sleep, Medical Outcomes Study Sleep; PBC, primary biliary cholangitis; PBC-40, primary biliary cholangitis-specific health-
related quality-of-life instrument; PGTB, Patient Global Therapeutic Benefit; PIC, Patient Impression of Change; sBA, serum bile acid; UDCA, 
ursodeoxycholic acid; ULN, upper limit of normal.
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and can significantly impair patients’ quality of life.(3) 
In particular, severe pruritus impairs sleep quality.(4) 
The etiology of pruritus is thought to be associated 
with increased serum bile acid (sBA) levels,(5) but 
the relationship is not fully understood. The patho-
physiology of pruritus involves multiple contributing 
factors, including bile acids, autotaxin, histamine, 
opioidergic tone, serotonin, and substance P.(6)
Ursodeoxycholic acid (UDCA) is the first-line 
pharmacologic intervention for the treatment of 
patients with PBC(7) and has been shown to improve 
serum biochemical markers of liver disease and 
transplant-free survival.(8-10) However, a significant 
improvement in pruritus is not typically observed.(11) 
Individuals also remain unresponsive to recommended 
agents for the treatment of cholestatic pruritus, which 
include cholestyramine, rifampicin, naltrexone, and 
sertraline.(12) New pharmacologic interventions are 
therefore needed.
Maralixibat chloride (SHP625; formerly LUM001 
or lopixibat) is a potent, apical, sodium-dependent, 
bile acid transporter competitive inhibitor (here on 
referred to as an ileal bile acid transporter [IBAT] 
inhibitor) with minimal systemic absorption.(13-15) 
In animal models of cholestasis, maralixibat blocked 
reabsorption of bile acids in the terminal ileum, 
thereby reducing enterohepatic recirculation to the 
liver and increasing fecal excretion of bile acids.(16) In 
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a rat partial bile duct ligation model of cholestasis, 
maralixibat reduced elevations in sBA levels, improved 
liver function, and reduced liver tissue damage com-
pared with control.(17) Reduced pruritus has been 
observed in patients with cholestatic liver disease 
following partial external biliary diversion surgery or 
administration of bile acid sequestrants, which also 
interrupt enterohepatic circulation of bile acids.(18-20) 
Use of a pharmacologic agent, such as maralixibat, to 
block reabsorption of bile acids may avoid the com-
plications and disfigurement associated with surgery. 
Here, we present the results of a placebo-controlled 
phase 2 study of the efficacy, safety, and tolerability of 
maralixibat in adults with PBC and pruritus.
Patients and Methods
etHiCs
This study (ClinicalTrials.gov identifier 
NCT01904058) was conducted in accordance with 
the Declaration of Helsinki as well as with applicable 
national legislation and the International Conference 
on Harmonisation Harmonised Tripartite Guideline 
for Good Clinical Practice (E6). All patients gave 
written informed consent before study enrollment.
stuDy population
This study enrolled adults aged 18-80 years who 
were diagnosed with PBC according to the American 
Association for the Study of Liver Diseases practice 
guidelines.(11) Patients had to have significant pruri-
tus as evidenced by an average daily score >4.0 on the 
10-point Adult Itch Reported Outcome (ItchRO™) 
questionnaire (Fig. 1) for 2 consecutive weeks during 
the screening period and to have been receiving 
UDCA for at least 6 months (stable dose for at least 
3 months before baseline) or have an intolerance 
to UDCA (no UDCA for at least 3 months before 
baseline). Changes in UDCA regimen were not per-
mitted during the study. Participants could also con-
tinue to receive rifampin, antihistamines, and opiate 
antagonists during the study if initiated at least 30 
days before screening and if the regimen was main-
tained throughout the study; the same was true for 
selective serotonin reuptake inhibitors and serotonin–
norepinephrine reuptake inhibitors if initiated at 
least 90 days before screening. Key exclusion criteria 
Fig. 1. Adult Itch Reported Outcome weekly sum score. Patients scored their itch each morning and evening. Data analysis included 
only the highest score available each day. Missing daily scores were not imputed. The weekly sum score for a given week was only 
calculated if daily scores were completed for at least 4 of the 7 days that week (compliant week). Missing daily scores for a compliant 
week were imputed using the average daily score for that week. If for a given week more than three daily scores were missing, then 
weekly sum scores from the most recent compliant week were used in a last observation carried forward format.
Days –7 to 1 
Start of treatment
weekly sum score (0-70) 
Difference between weekly sum scores (0-70)  
End of treatment
weekly sum score (0-70) 
On treatment Off treatment 
Assessed daily 
Primary efficacy endpointExample of the Adult Itch Reported Outcome
morning assessment questionnaire
Days 84 to 91
(or the 7 days before
early termination) 
How would you rate the
worst itch you experienced
from the time you went to
bed last night until waking
up this morning?
109876543210
Worst
possible
itch
No
itch
?
3:38
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were evidence of biliary obstruction or overt malig-
nancy on ultrasound or equivalent imaging in the 12 
months before the screening visit, evidence of signif-
icant concomitant significant liver diseases, advanced 
clinical complications of PBC or clinically significant 
hepatic decompensation, bile acid resin use within 30 
days before randomization, and total bilirubin levels 
of more than twice the upper limit of normal (ULN) 
or alanine aminotransferase (ALT) or aspartate ami-
notransferase (AST) levels more than 5-fold ULN at 
screening.
stuDy Design
The study was conducted between August 2013 
and April 2015 at 24 locations, including medical 
centers, clinics, and hospitals, in the United States, 
United Kingdom, and Canada and comprised a 
screening period of up to 5 weeks, a 13-week treat-
ment period, and a 4-week safety follow-up period 
(Fig. 2). The 13-week treatment period comprised 
2-4 weeks of dose escalation followed by 9-11 
weeks of stable dose treatment. To allow patients to 
acclimate to the study drug, maralixibat was initiated 
at 2.5 mg/day and increased at weekly intervals to 5, 
10, or 20 mg/day. Patients who did not complete to 
week 13 were invited to attend an early termination 
(ET) visit.
Two dose cohorts were planned (cohort A, mara-
lixibat 10 mg; cohort B, maralixibat 5 mg or 20 mg). 
Dose selection for cohort B was guided by tolerance 
to maralixibat in the first 18 patients to complete 4 
weeks of treatment in cohort A. If dosing of active 
treatment had to be reduced, suspended, or stopped 
owing to gastrointestinal intolerance in 5 or more of 
these 18 patients, then patients in cohort B would 
receive maralixibat 5 mg; otherwise, patients would 
receive maralixibat 20 mg.
In each dose cohort, patients were randomized 2:1 
using an interactive web response system to receive 
once-daily oral maralixibat or matching placebo. The 
sponsor prepared the randomization list. All patients, 
monitors, study center personnel, and the spon-
sor were blinded to treatment throughout the study. 
Further details of the randomization procedure can be 
found in the Supporting Materials.
Fig. 2. Study design. Dose selection for cohort B was guided by the tolerability of maralixibat in the first 18 patients who completed 4 
weeks of treatment in cohort A; the decision was based on the number of patients who lowered their dose or suspended or stopped active 
treatment owing to gastrointestinal intolerance related to the maralixibat (≥5 patients, cohort B would have received 5 mg maralixibat; 
<5 patients, cohort B would have received 20 mg maralixibat). Clinic visits were scheduled at baseline (week 0) and weeks 2, 4, 8, and 
13. Telephone contact was scheduled at weeks 1, 3, and 17 (follow-up call).
5 mg/day 
10 mg/day 
20 mg/day 
2.5 mg/day 
Maralixibat  10 mg/day
Maralixibat  20 mg/day
Screening 
up to 5 weeks 
Dose escalation 
2-4 weeks 
Stable dose treatment 
9-11 weeks 
Follow-up 
4 weeks 
Cohort A 
Cohort B 
Placebo Cohort A 
Cohort B 
Maralixibat  5 mg/day
Cohort B 
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pRimaRy eFFiCaCy outCome
The primary efficacy outcome was change from 
baseline to study endpoint (week 13/ET) in pruritus 
as measured by the Adult ItchRO™ weekly sum score 
(Fig. 1). Patients completed the Adult ItchRO™ elec-
tronic diary twice daily (morning and evening); itch 
severity was rated from 0 (no itching) to 10 (very 
severe itching). The highest score from the morning 
and evening assessments was used as the daily score, 
and weekly sum scores were calculated as the sum of 
daily scores over the 7 days before each visit.
seConDaRy eFFiCaCy 
outComes
Secondary efficacy outcomes, assessed at weeks 4, 
8, 13, and 13/ET, were Adult ItchRO™ weekly sum 
scores, fasting sBA levels, serum 7α-hydroxy-4-cho-
lesten-3-one (C4) levels, alkaline phosphatase (ALP) 
levels,(21) and 5-D Itch scores. 5-D Itch is a validated, 
self-reported measure of pruritus that includes five 
domains (duration, degree, direction, disability, and 
distribution) and gives a total score ranging from 5 
(no itching) to 25 (most severe itching).(22)
eXploRatoRy eFFiCaCy 
outComes
Exploratory efficacy outcomes included changes 
from baseline to weeks 4, 8, 13, and 13/ET in levels 
of ALT and AST and gamma-glutamyl transferase 
(GGT).(21) Changes from baseline for levels of fibro-
blast growth factor (FGF) 19 and FGF-21 (potential 
regulators of bile acid synthesis),(23) total and conju-
gated bilirubin and autotaxin,(24) and total cholesterol 
and low-density lipoprotein cholesterol (LDL-C)(21) 
were assessed at weeks 4, 13, and 13/ET.
Changes from baseline in PBC-40 domain scores 
were assessed at weeks 4, 8, 13, and 13/ET. PBC-40 is 
a validated, patient-derived, PBC-specific, health-re-
lated quality-of-life measure comprising 40 items, each 
scored on a scale from 1 (least impact) to 5 (great-
est impact) and distributed across six domains (itch, 
emotional, cognitive, symptoms, social, and fatigue). 
Individual item scores were summed for each domain, 
with higher scores indicating poorer quality of life.(25)
Changes from baseline in Medical Outcomes 
Study Sleep (MOS-Sleep) Scale scores were assessed 
at weeks 4, 13, and 13/ET. The MOS-Sleep Scale is 
a self-reported 12-item measure evaluating six dimen-
sions of sleep in patients with chronic illness (sleep 
disturbance, snoring, awaken short of breath or head-
ache, sleep adequacy, somnolence, sleep quantity/
optimal sleep indicator). Items were scored, converted 
(range, 0-100), and averaged according to the MOS-
Sleep Scale User’s Manual,(26) with higher scores indi-
cating greater sleep dysfunction. MOS-Sleep Scale 
composite scores were also determined (sleep prob-
lems index I [6/12 items] and sleep problems index II 
[9/12 items]). Individuals were considered to have had 
optimal sleep if, on average, they slept 7-8 hours each 
night during the past 4 weeks.
Self-Administered Patient Impression of Change 
(PIC) and Patient Global Therapeutic Benefit 
(PGTB) were assessed at week 13 and week 13/
ET. The PIC scale is a self-reported assessment 
of itching that is scored from 1 (much better) to 7 
(much worse). Treatment response was predefined as 
a PIC score ≤3. The PGTB scale is a self-reported 
assessment of whether treatment benefit in terms 
of a reduction in itching outweighs the side effects 
and is scored from 1 (definitely) to 5 (definitely 
not). Treatment response was predefined as a PGTB 
score ≤2.
BioanalytiCal metHoDology
Levels of sBA and C4 were determined using 
validated routine liquid chromatography–mass spec-
trometry methodology. Levels of FGF-19, FGF-21, 
and autotaxin were determined using commercially 
available enzyme-linked immunosorbent assays. See 
Supporting Materials for further information. All 
chemistry analytes (ALP, ALT, AST, conjugated bil-
irubin, GGT, total bilirubin) and lipid panel analytes 
(LDL-C and total cholesterol) were analyzed col-
orimetrically using commercially available tests at a 
central laboratory (Clinical Reference Laboratory, 
Lenexa, KS).
saFety assessments
Assessment of the safety and tolerability of mara-
lixibat included evaluation of adverse events (AEs) 
and vital signs. AEs were coded using the Medical 
Dictionary for Regulatory Activities, version 16.0, and 
graded as mild, moderate, or severe in the opinion 
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of the site investigator reporting the AE, using the 
Common Terminology Criteria for AEs, version 4.0. 
Predefined AEs of special interest included gastroin-
testinal disorders.
statistiCal analysis
Efficacy was assessed in the intent-to-treat (ITT) 
population, which included all randomized patients. 
Data for patients receiving placebo in cohorts A and 
B were pooled and compared with combined data for 
patients receiving maralixibat 10 mg or 20 mg (mara-
lixibat overall) and with data from each maralixibat 
dose group.
The study design required randomization of 60 
patients (maralixibat, n = 40; placebo, n = 20) to pro-
vide 80% power to detect an effect size of 0.780 and 
90% power to detect an effect size of 0.903 for the 
difference between active treatment and placebo in 
mean change from baseline to week 13/ET in the 
Adult ItchRO™ weekly sum score (α = 0.05). Because 
no published information was available, these target 
effect sizes were based on other itch measures in this 
study population and on clinical judgment.
Between-group differences in the primary efficacy 
outcome were assessed by analysis of covariance, with 
treatment and stratified ALP level as factors and base-
line Adult ItchRO™ weekly sum score as a covariate. 
Least-squares (LS) mean changes from baseline with 
95% confidence intervals (CIs) were calculated for 
each treatment group and the group receiving placebo. 
LS mean differences between maralixibat and placebo 
with 95% CIs were calculated with pairwise treatment 
P values.
All secondary and exploratory outcomes involving 
continuous measures were analyzed using an anal-
ysis of covariance model, adjusted for the baseline 
value for each outcome measure. Exploratory out-
comes involving categorical data were analyzed using 
a Cochran–Mantel−Haenszel test. All P values were 
considered nominal (unadjusted for multiplicity). 
Therefore, discussion of the results for secondary and 
exploratory outcomes is based on whether 95% CIs 
overlap between the maralixibat and placebo groups.
A hierarchical testing sequence was applied. If 
the difference for both maralixibat doses combined 
(maralixibat overall) versus placebo was statistically 
significant (P < 0.05), then further analyses of mara-
lixibat 20 mg versus placebo and maralixibat 10 mg 
versus placebo were performed. A P value was con-
sidered nominal if the value from the preceding test 
was ≥0.05.
Correlations between change (absolute and per-
centage) in Adult ItchRO™ weekly sum score and 
levels of sBA, C4, or FGF-19 were explored in post 
hoc analyses using Spearman correlation statistics. The 
proportions of patients with a response (reduction in 
sBA levels of at least 70% and an improvement of at 
least 2.5 points on the Adult ItchRO™ from baseline 
to week 13/ET) were calculated in the overall study 
population (maralixibat and placebo groups com-
bined) in a post hoc subgroup analysis that stratified 
patients by baseline sBA level (greater than 3 times 
ULN and 3 times ULN or less). All post hoc statistics 
were considered descriptive rather than inferential.
Safety outcomes were assessed descriptively in all 
patients who had received at least one dose of the 
study drug (safety population; these patients were the 
same as those in the ITT population); inferential sta-
tistics were not performed.
Results
Disposition anD Baseline 
CHaRaCteRistiCs oF patients
Of the 66 patients randomized, 61 patients (92.4%) 
completed the 13-week study (Fig. 3). All randomized 
patients received at least one dose of the study drug 
and had at least one postbaseline Adult ItchRO™ 
assessment.
The majority of patients were receiving ongoing 
treatment with UDCA during the study (maralixibat 
10 mg, 100.0%; maralixibat 20 mg, 90.5%; placebo, 
79.2%). The numbers of patients receiving stable 
concomitant therapy for pruritus in the maralixibat 
overall (n = 42) and placebo (n = 24) cohorts, respec-
tively, were 21 (50.0%) and 9 (37.5%): antihistamines 
(11 [26.2%]; 5 [20.8%]), analgesics (5 [11.9%]; 3 
[12.5%]), lipid-modifying agents (4 [9.5%]; 1 [4.2%]), 
psychoanaleptics (2 [4.8%]; 1 [4.2%]), psycholep-
tics (2 [4.8%]; 0 [0.0%]), and other nervous system 
drugs (1 [2.4%]; 0 [0.0%]) (Supporting Table S1). 
Some patients received more than one concomitant 
medication.
Most baseline characteristics were well matched 
across the treatment groups (Table 1), although sBA 
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levels (mean ± SD) were numerically lower with 
maralixibat overall (42.8 ± 69.99 μmol/L) than with 
placebo (55.8 ± 68.41 μmol/L), and proportionately 
more patients receiving maralixibat (85.7%) had a 
liver biopsy consistent with PBC than patients in the 
placebo group (75.0%).
eFFiCaCy outComes
pruritus
Adult ItchRO™ weekly sum scores significantly 
decreased from baseline to week 13/ET in the mara-
lixibat overall group (LS mean change, –26.5; 95% CI, 
Fig. 3. Patient disposition. Percentages are based on the ITT population.
Excluded (N = 21)
• Failed to meet eligibility criteria (n = 12)
• Withdrawal by patient (n = 7)
• Lost to follow-up (n = 2)
Allocated to maralixibat 10 mg 
(cohort A)
• Received drug (n = 21)
• Did not receive drug (n = 0)
Allocated to placebo
• Received drug (n = 24)
• Did not receive drug (n = 0)
Discontinued (n = 3, 14.3%)
• Adverse event (n = 2)
• Withdrawal by patient (n = 1)
Discontinued (n = 0, 0.0%)
Included in analyses (n = 21)
• ITT population (n = 21)
Completed (n = 18, 85.7%)
Screened (N = 87)
Enrolled (N = 66)
Allocated to maralixibat 20 mg 
(cohort B)
• Received drug (n = 21)
• Did not receive drug (n = 0)
Included in analyses (n = 21)
• ITT population (n = 21)
Completed (n = 21, 100%)
Discontinued (n = 2, 8.3%)
• Pregnancy (n = 1)
• Withdrawal by patient (n = 1)
Included in analyses (n = 24)
• ITT population (n = 24)
Completed (n = 22, 91.7%)
taBle 1. Baseline DemogRapHiCs anD Disease CHaRaCteRistiCs
Maralixibat
10 mg
(n = 21)
Maralixibat
20 mg
(n = 21)
Maralixibat Overall
(n = 42)
Placebo
(n = 24)
Patient demographics
Age, years 54.7 ± 12.74 53.5 ± 10.53 54.1 ± 11.56 52.0 ± 9.32
Female sex, n (%) 20 (95.2) 17 (81.0) 37 (88.1) 23 (95.8)
Disease characteristics
Adult ItchRO™ weekly sum score 48.1 ± 13.36 52.1 ± 13.78 50.1 ± 13.56 51.8 ± 12.14
Serum bile acids, μmol/L 33.1 ± 30.59 52.5 ± 94.39 42.8 ± 69.99 55.8 ± 68.41
ALP, U/L 288.2 ± 193.91 257.6 ± 190.38 272.9 ± 190.43 264.9 ± 152.27
All values are mean ± SD unless otherwise stated.
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–31.8, –21.2; P < 0.0001) and the placebo group 
(–23.4; 95% CI, –30.3, –16.4; P < 0.0001) (Fig. 4A; 
Supporting Table S2). However, the reduction was 
not significantly different between placebo and mara-
lixibat overall (LS mean difference, –3.1; 95% CI, 
–11.9, 5.6; P = 0.48), maralixibat 20 mg (–4.0; 95% 
Fig. 4. Adult ItchRO™ weekly sum scores and serum bile acids. (A,B) Change from baseline and (C,D) difference in change 
for maralixibat versus placebo. (A,C) Adult ItchRO™ weekly sum scores and (B,D) sBA levels are presented at each time point. 
*P < 0.05 (analysis of covariance model); ***P < 0.0001. In panel B, boxes represent the IQR; the band within each box represents the 
median; the upper and lower error bars, respectively, represent the maximum and minimum data points excluding outliers; small data 
points represent outliers (individual data points outside 1.5 × IQR); and the bold, single, large data points represent mean change. All 
statistical comparisons except those for the primary outcome were considered nominal (not adjusted for multiplicity). Abbreviation: 
IQR, interquartile range.
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CI, –14.2, 6.2; P = 0.44), or maralixibat 10 mg (–2.3; 
95% CI, –12.6, 8.0; P = 0.66) (Fig. 4C; Supporting 
Table S2). Reductions from baseline in itch were 
similar in all groups at weeks 8 and 13 (Fig. 4C; 
Supporting Table S2). Similar findings were observed 
when UDCA use was included as a factor in the 
analysis of covariance model and when only patients 
with UDCA use were assessed (data not shown).
Scores for the 5-D Itch measure and the PBC-40 
Itch domain also decreased from baseline to weeks 
4, 8, 13, and 13/ET in all groups but did not differ 
between the maralixibat and placebo groups (Table 2; 
Supporting Table S2).
serum Bile acids and synthesis 
Regulation
In the maralixibat groups, fasting sBA levels 
decreased from baseline to weeks 4, 8, 13, and 13/
ET, whereas increases were observed in the placebo 
group (Fig. 4B; Supporting Table S3). The LS mean 
reduction in fasting sBA levels from baseline to week 
13/ET was numerically greater in the maralixibat 
20 mg group (–17.0 µmol/L; 95% CI, –36.9, 2.9) than 
in the 10 mg group (–11.4 µmol/L; 95% CI, –31.4, 
8.5) (Fig. 4B; Supporting Table S3). In the placebo 
group, the LS mean increase in fasting sBA levels 
from baseline to week 13/ET was 10.1 µmol/L (95% 
CI, –8.7, 28.8).
Levels of C4 increased from baseline to week 13/
ET with both doses of maralixibat and decreased with 
placebo (Table 3; Supporting Table S3). LS mean 
increases in C4 levels from baseline to week 13/ET 
were 21.5 ng/mL (95% CI, 10.9, 32.1) with maralix-
ibat 10 mg and 5.5 ng/mL (95% CI, –5.2, 16.2) with 
maralixibat 20 mg compared with a decrease of 2.2 
ng/mL (95% CI, –12.5, 8.1) in the placebo group 
(Table 3; Supporting Table S3).
No clear trends were observed for LS mean changes 
in FGF-19 and FGF-21 (Table 3; Supporting 
Table S3).
markers of Cholestasis and 
Hepatocellular injury
Changes in levels of ALP, GGT, total or conju-
gated bilirubin, ALT, and AST from baseline to week 
13/ET did not differ between the maralixibat and pla-
cebo groups (Table 3; Supporting Table S3).
Levels of autotaxin, a marker shown to correlate with 
severity of cholestatic itch in PBC,(27) decreased from 
baseline to week 13/ET in the maralixibat groups and 
increased in the placebo group (Table 3; Supporting 
Table S3). The LS mean reductions in autotaxin lev-
els from baseline to week 13/ET were –167.7 ng/
mL (95% CI, –275.6, –59.8) in the maralixibat 10 mg 
group and –82.5 ng/mL (95% CI, –188.9, 23.9) in the 
maralixibat 20 mg group compared with an LS mean 
increase of 62.8 ng/mL (95% CI, –42.5, 168.1) in the 
placebo group (Table 3; Supporting Table S3).
lipid metabolism
Total cholesterol decreased from baseline to week 
13/ET in the maralixibat groups, with a greater LS 
mean reduction in the 10 mg group (–15.4 mg/mL; 
95% CI, –28.2, –2.7) than in the 20 mg group (–6.3 mg/
mL; 95% CI, –18.8, 6.2) (Table 3; Supporting Table 
S3). In contrast, total cholesterol increased in the pla-
cebo group (LS mean change, 2.3 mg/mL; 95% CI, 
–9.4, 14.0). Reductions from baseline in LDL-C were 
observed in the maralixibat and placebo groups at 
week 13/ET; LS mean reductions were numerically 
greater with maralixibat 10 mg (–13.7 mg/mL; 95% 
CI, –24.2, –3.1) and 20 mg (–11.6 mg/mL; 95% CI, 
–21.7, –1.5) than with placebo (–4.0 mg/mL; 95% CI, 
–13.6, 5.6).
Quality of life, sleep, and overall 
treatment Benefit
Comparisons of changes in PBC-40 domain scores 
in the maralixibat and placebo groups did not indicate 
any clinically meaningful improvements in favor of 
maralixibat for the itch, emotional, cognitive, symp-
toms, social, or fatigue domains (Table 2; Supporting 
Table S2).
Changes in MOS-Sleep Scale domain scores and 
the proportion of patients achieving optimal sleep did 
not differ between the maralixibat and placebo groups 
(Table 2; Supporting Table S2).
Despite no difference in the primary outcome of 
the study, more patients in the maralixibat groups 
perceived a treatment benefit at week 13 than in the 
placebo group as assessed by responses on the PIC 
scale (maralixibat overall, 89.7%; placebo, 68.2%; 
P = 0.034). The response rate as assessed on the 
PGTB scale was numerically greater in the maralixibat 
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taBle 2. CHanges in pRuRitus, Quality oF liFe, sleep, anD patient peRCeption oF 
tReatment BeneFits FRom Baseline to WeeK 13/et
Maralixibat
10 mg
(n = 21)
Maralixibat
20 mg
(n = 21)
Maralixibat 
Overall
(n = 42)
Placebo
(n = 24)
5-D Itch score
LS mean change from baseline (95% CI) –6.9 –6.7 –6.8 –6.3
(–8.9, –4.8)‡ (–8.8, –4.6)‡ (–8.2, –5.3)‡ (–8.3, –4.4)‡
LS mean difference from placebo (95% CI) –0.5 –0.4 –0.5 N/A
(–3.4, 2.3) (–3.2, 2.5) (–2.9, 2.0)
PBC-40 domain score
Itch (3 items)
LS mean change from baseline (95% CI) –4.0 –4.1 –4.1 –3.8
(–5.3, –2.8)‡ (–5.4, –2.9)‡ (–5.0, –3.2)‡ (–5.0, –2.6)‡
LS mean difference from placebo (95% CI) –0.3 –0.4 –0.3 N/A
(–2.0, 1.5) (–2.1, 1.4) (–1.8, 1.2)
Emotional (3 items)
LS mean change from baseline (95% CI) –1.4 –1.2 –1.3 –0.5
(–2.2, –0.7)‡ (–2.0, –0.4)† (–1.9, –0.8)‡ (–1.3, 0.2)
LS mean difference from placebo (95% CI) –0.9 –0.7 –0.8 N/A
(–2.0, 0.2) (–1.7, 0.4) (–1.7, 0.1)
Cognitive (6 items)
LS mean change from baseline (95% CI) –1.5 –0.5 –1.0 –1.6
(–3.0, –0.1)* (–2.0, 0.9) (–2.0, 0.0)* (–3.0, –0.3)*
LS mean difference from placebo (95% CI) 0.1 1.1 0.6 N/A
(–1.8, 2.1) (–0.8, 3.1) (–1.1, 2.3)
Symptoms (7 items)
LS mean change from baseline (95% CI) –0.8 –0.4 –0.6 –1.8
(–2.3, 0.7) (–1.9, 1.1) (–1.6, 0.4) (–3.2, –0.4)*
LS mean difference from placebo (95% CI) 1.0 1.4 1.2 N/A
(–1.0, 3.0) (–0.7, 3.4) (–0.6, 2.9)
Social (10 items)
LS mean change from baseline (95% CI) –2.0 –2.8 –2.4 –2.1
(–4.4, 0.4) (–5.2, –0.3)* (–4.1, –0.7)† (–4.5, 0.2)
LS mean difference from placebo (95% CI) 0.1 –0.6 –0.2 N/A
(–3.2, 3.5) (–4.0, 2.7) (–3.1, 2.6)
Fatigue (11 items)
LS mean change from baseline (95% CI) –2.3 –2.8 –2.5 –4.9
(–5.5, 0.9) (–6.0, 0.4) (–4.8, –0.3)* (–7.9, –1.8)†
LS mean difference from placebo (95% CI) 2.6 2.1 2.3 N/A
(–1.8, 7.0) (–2.3, 6.5) (–1.4, 6.1)
MOS-Sleep Scale score
Sleep disturbances (4 items)
LS mean change from baseline (95% CI) –9.2 –9.0 –9.1 –15.6
(–18.8, 0.5) (–18.6, 0.7) (–15.9, –2.3)* (–24.8, –6.4)†
LS mean difference from placebo (95% CI) 6.4 6.6 6.5 N/A
(–6.9, 19.8) (–6.7, 19.9) (–4.9, 18.0)
Snoring (1 item)
LS mean change from baseline (95% CI) –8.5 –5.7 –7.1 0.3
(–17.5, 0.6) (–14.9, 3.6) (–13.5, –0.6)* (–8.4, 8.9)
(Continued)
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Maralixibat
10 mg
(n = 21)
Maralixibat
20 mg
(n = 21)
Maralixibat 
Overall
(n = 42)
Placebo
(n = 24)
LS mean difference from placebo (95% CI) –8.7 –5.9 –7.3 N/A
(–21.2, 3.7) (–18.8, 6.9) (–18.2, 3.5)
Awaken short of breath or headache (1 item)
LS mean change from baseline (95% CI) –6.3 –3.0 –4.6 –0.9
(–16.4, 3.9) (–13.2, 7.2) (–11.8, 2.6) (–10.5, 8.8)
LS mean difference from placebo (95% CI) –5.4 –2.1 –3.7 N/A
(–19.4, 8.7) (–16.2, 12.0) (–15.8, 8.3)
Sleep adequacy (2 items)
LS mean change from baseline (95% CI) 7.1 2.1 4.6 3.9
(–3.8, 18.0) (–8.8, 13.0) (–3.1, 12.3) (–6.4, 14.2)
LS mean difference from placebo (95% CI) 3.2 –1.8 0.7 N/A
(–11.8, 18.2) (–16.8, 13.2) (–12.1, 13.5)
Somnolence (3 items)
LS mean change from baseline (95% CI) –5.0 –10.3 –7.7 –11.7
(–14.3, 4.2) (–19.6, –1.1)* (–14.2, –1.2)* (–20.5, –3.0)†
LS mean difference from placebo (95% CI) 6.7 1.4 4.1 N/A
(–6.0, 19.4) (–11.3, 14.1) (–6.8, 15.0)
Sleep problems index I (6 items)
LS mean change from baseline (95% CI) –8.3 –5.7 –7.0 –8.8
(–16.0, –0.6)* (–13.4, 2.0) (–12.5, –1.5)* (–16.1, –1.4)*
LS mean difference from placebo (95% CI) 0.5 3.1 1.8 N/A
(–10.2, 11.1) (–7.6, 13.7) (–7.4, 10.9)
Sleep problems index II (9 items)
LS mean change from baseline (95% CI) –7.8 –7.2 –7.5 –10.9
(–15.2, –0.4)* (–14.6, 0.2) (–12.7, –2.3)† (–17.9, –3.9)†
LS mean difference from placebo (95% CI) 3.1 3.8 3.4 N/A
(–7.1, 13.3) (–6.5, 13.9) (–5.3, 12.2)
Sleep quantity, number of hours (1 item)
LS mean change from baseline (95% CI) 0.1 0.5 0.3 0.3
(–0.4, 0.6) (0.0, 1.0) (0.0, 0.6) (–0.2, 0.7)
LS mean difference from placebo (95% CI) –0.2 0.2 0.0 N/A
(–0.8, 0.5) (–0.5, 0.9) (–0.6, 0.6)
Optimal sleep indicator (1 item)
Baseline
n 21 21 42 24
Yes, n (%) 6 (28.6) 8 (38.1) 14 (33.3) 4 (16.7)
No, n (%) 15 (71.4) 13 (61.9) 28 (66.7) 20 (83.3)
P value versus placebo 0.34 0.11 0.14 N/A
Week 13/ET
n 21 21 42 23
Yes, n (%) 9 (42.9) 5 (23.8) 14 (33.3) 8 (34.8)
No, n (%) 12 (57.1) 16 (76.2) 28 (66.7) 15 (65.2)
P value versus placebo 0.59 0.42 0.91 N/A
Patient Impression of Change
Week 13/ET
n 21 21 42 22
Responder (score ≤3), n (%) 19 (90.5) 17 (81.0) 36 (85.7) 15 (68.2)
taBle 2. (ContinueD)
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overall group (79.5%) than the placebo group (63.6%) 
(Supporting Table S4).
Post Hoc analyses
There were no strong correlations between percent-
age changes from baseline in Adult ItchRO™ weekly 
sum score and corresponding changes in levels of 
sBA, C4, or FGF-19 at any assessed time point in the 
maralixibat or placebo groups (Supporting Table S5).
A response to treatment across the overall study 
population was observed in proportionately more 
patients who had abnormally high sBA levels at 
baseline (34.5%, 10/29 patients) than in those with 
baseline sBA levels 3 times ULN or less (5.4%, 2/37 
patients).
saFety outComes
Duration of exposure (mean ± SD) to all doses of 
maralixibat was 88.5 ± 14.29 days and to placebo was 
87.9 ± 15.50 days (Supporting Fig. S1).
treatment-emergent aes
In the maralixibat overall and placebo groups, AEs 
were reported in 97.6% and 70.8% of patients, respec-
tively (Table 4); the incidence of AEs in the maralix-
ibat groups did not appear to be dose related. Of the 
41 patients with AEs receiving maralixibat, the max-
imum severity of reported AEs was mild in 31.7%, 
moderate in 53.7%, and severe in 14.6%. AEs were 
mild or moderate in severity in all patients with AEs 
receiving placebo (58.8% and 41.2%, respectively). The 
AEs reported in 10% or more of patients in either 
the maralixibat overall or placebo groups, respec-
tively, were diarrhea (61.9%; 25.0%), abdominal pain 
(23.8%; 4.2%), abdominal pain upper (23.8%; 8.3%), 
nausea (23.8%; 16.7%), cough (11.9%; 0.0%), head-
ache (11.9%; 33.3%), abdominal distension (7.1%; 
12.5%), and pruritus (2.4%; 12.5%). No deaths were 
reported during the study.
Two patients in the maralixibat overall group dis-
continued the study drug owing to an AE. One patient 
discontinued owing to moderate abdominal pain while 
receiving the 5-mg dose of maralixibat during dose 
escalation. The second patient discontinued owing to 
severe diarrhea during stable dosing with maralixibat 
10 mg. These events were considered related to and 
possibly related to the study drug, respectively. In the 
placebo group, no patients discontinued the study 
drug owing to an AE.
Serious AEs were reported in 3 patients receiving 
maralixibat. In the maralixibat 10-mg group, severe 
myocardial infarction, not considered to be treatment 
related, was reported in 1 patient, and severe abdom-
inal pain, considered possibly treatment related, was 
reported in another patient. Three serious AEs (a 
severe pleural effusion event and two severe gastro-
intestinal hemorrhage events), none of which were 
considered treatment related, were reported by a third 
patient in the maralixibat 20-mg group. No serious 
AEs were reported in patients receiving placebo.
Maralixibat
10 mg
(n = 21)
Maralixibat
20 mg
(n = 21)
Maralixibat 
Overall
(n = 42)
Placebo
(n = 24)
Nonresponder (score >3), n (%) 2 (9.5) 4 (19.0) 6 (14.3) 7 (31.8)
P value versus placebo 0.07 0.39 0.10 N/A
Patient Global Therapeutic Benefit
Week 13/ET
n 21 21 42 22
Responder (score ≤2), n (%) 14 (66.7) 17 (81.0) 31 (73.8) 14 (63.6)
Nonresponder (score >2), n (%) 7 (33.3) 4 (19.0) 11 (26.2) 8 (36.4)
P value versus placebo 0.80 0.24 0.40 N/A
*P < 0.05; †P < 0.01; ‡P < 0.001 (analysis of covariance model with treatment group, ALP level [strata] and treatment group by ALP 
level interaction as factors, and baseline value as a covariate). Categorical data were analyzed using a Cochran–Mantel−Haenszel test. 
All P values are nominal (not adjusted for multiplicity).
Abbreviation: N/A, not applicable.
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taBle 3. CHanges in laBoRatoRy paRameteRs FRom Baseline to WeeK 13/et
Maralixibat
10 mg
(n = 21)
Maralixibat
20 mg
(n = 21)
Maralixibat Overall
(n = 42)
Placebo
(n = 24)
Bile acid synthesis
C4, ng/mL
LS mean change from baseline (95% CI) 21.5 5.5 13.5 –2.2
(10.9, 32.1)‡ (–5.2, 16.2) (6.0, 21.0)‡ (–12.5, 8.1)
LS mean difference from placebo (95% CI) 23.7 7.7 15.7 N/A
(8.9, 38.5)† (–7.2, 22.7) (2.9, 28.5)*
Potential regulators of bile acid synthesis
FGF-19, pg/mL
LS mean change from baseline (95% CI) 7.1 –31.8 –12.3 –5.8
(–31.1, 45.4) (–70.9, 7.3) (–39.3, 14.6) (–42.5, 30.9)
LS mean difference from placebo (95% CI) 12.9 –26.0 –6.5 N/A
(–39.7, 65.5) (–80.8, 28.8) (–52.6, 39.5)
FGF-21, pg/mL
LS mean change from baseline (95% CI) –32.2 28.9 –1.7 20.8
(–99.7, 35.3) (–33.6, 91.4) (–47.1, 43.8) (–39.3, 80.9)
LS mean difference from placebo (95% CI) –53.0 8.1 –22.4 N/A
(–143.5, 37.5) (–78.5, 94.7) (–97.8, 52.9)
Cholestasis
ALP, U/L
LS mean change from baseline (95% CI) –7.4 17.1 4.9 7.3
(–41.8, 27.0) (–17.3, 51.5) (–19.5, 29.2) (–24.7, 39.3)
LS mean difference from placebo (95% CI) –14.7 9.8 –2.4 N/A
(–61.7, 32.3) (–37.2, 56.8) (–42.6, 37.8)
Autotaxin, ng/mL
LS mean change from baseline (95% CI) –167.7 –82.5 –125.1 62.8
(–275.6, –59.8)† (–188.9, 23.9) (–201.1, –49.1)† (–42.5, 168.1)
LS mean difference from placebo (95% CI) –230.5 –145.3 –187.9 N/A
(–381.9, –79.0)† (–296.1, 5.6) (–318.8, –56.9)†
GGT, U/L
LS mean change from baseline (95% CI) 28.6 61.9 45.3 45.0
(–46.5, 103.7) (–13.1, 137.0) (–7.7, 98.2) (–24.6, 114.6)
LS mean difference from placebo (95% CI) –16.4 16.9 0.3 N/A
(–118.7, 85.9) (–85.5, 119.4) (–87.2, 87.7)
Total bilirubin, mg/dL
LS mean change from baseline (95% CI) 0.00 0.09 0.04 –0.05
(–0.13, 0.13) (–0.04, 0.21) (–0.05, 0.13) (–0.17, 0.07)
LS mean difference from placebo (95% CI) 0.05 0.14 0.09 N/A
(–0.12, 0.22) (–0.04, 0.31) (–0.06, 0.24)
Conjugated bilirubin, mg/dL
LS mean change from baseline (95% CI) 0.004 0.05 0.03 –0.01
(–0.06, 0.07) (–0.02, 0.11) (–0.02, 0.07) (–0.08, 0.05)
LS mean difference from placebo (95% CI) 0.02 0.06 0.04 N/A
(–0.08, 0.11) (–0.03, 0.15) (–0.04, 0.12)
Hepatocellular injury
ALT, U/L
LS mean change from baseline (95% CI) 0.7 1.7 1.2 1.1
(–12.7, 14.1) (–11.8, 15.3) (–8.3, 10.8) (–11.5, 13.7)
(Continued)
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gastrointestinal aes
The overall incidence of gastrointestinal AEs was 
higher in the maralixibat groups (20 mg, 81.0%; 
10 mg, 75.0%) than in the placebo group (50.0%) 
(Supporting Table S6). Gastrointestinal AEs were 
reported in proportionally fewer patients during sta-
ble dosing (maralixibat overall, 31.7%; placebo, 8.7%) 
than during dose escalation (maralixibat overall, 
61.9%; placebo, 45.8%). The majority of gastrointesti-
nal AEs had resolved by the end of the study without 
dose interruption or drug discontinuation.
Vital signs
There were no clinically meaningful changes in 
vital signs in any treatment group.
Discussion
Inhibition of ileal bile acid reuptake in this 13-week, 
randomized, double-blind, placebo-controlled trial of 
maralixibat in adults with PBC did not significantly 
improve pruritus compared with placebo. However, 
the lessons learned from this rigorously designed and 
executed trial are indispensable for understanding 
both the importance of the design of trials with a pri-
mary endpoint of pruritus and the therapeutic win-
dow of bile acid reuptake inhibition as a therapeutic 
strategy for cholestatic pruritus.
In this study, pruritus improved significantly from 
baseline to week 13/ET in both the maralixibat and 
placebo groups, with LS mean changes in ItchRO™ 
weekly sum scores of –26.5 and –23.4, respectively. 
The magnitude of this improvement from baseline 
(maralixibat overall, 52%; placebo, 47%), based on 
the means at baseline and week13/ET in ItchRO™ 
weekly sum scores, was similar to that reported in tri-
als of medications recommended in practice guidelines 
for cholestatic pruritus, such as naltrexone and rifam-
pin.(7,28) This finding unquestionably highlights both 
the importance of having a placebo group and that 
the placebo effect can be large when using subjective 
patient-reported outcomes as the primary endpoint. 
Without this pronounced placebo effect, the observed 
reduction in pruritus in the maralixibat group may 
have been viewed as beneficial. Perhaps one way of 
Maralixibat
10 mg
(n = 21)
Maralixibat
20 mg
(n = 21)
Maralixibat Overall
(n = 42)
Placebo
(n = 24)
LS mean difference from placebo (95% CI) –0.4 0.6 0.1 N/A
(–18.7, 18.0) (–18.0, 19.3) (–15.7, 16.0)
AST, U/L
LS mean change from baseline (95% CI) –5.4 0.9 –2.3 5.7
(–18.9, 8.0) (–12.7, 14.4) (–11.9, 7.3) (–7.0, 18.4)
LS mean difference from placebo (95% CI) –11.2 –4.9 –8.0 N/A
(–29.8, 7.5) (–23.7, 13.9) (–24.1, 8.1)
Lipid metabolism
Total cholesterol, mg/mL
LS mean change from baseline (95% CI) –15.4 –6.3 –10.9 2.3
(–28.2, –2.7)* (–18.8, 6.2) (–19.7, –2.0)* (–9.4, 14.0)
LS mean difference from placebo (95% CI) –17.7 –8.6 –13.2 N/A
(–35.1, –0.4)* (–25.7, 8.5) (–27.8, 1.5)
LDL-C, mg/mL
LS mean change from baseline (95% CI) –13.7 –11.6 –12.6 –4.0
(–24.2, –3.1)* (–21.7, –1.5)* (–19.8, –5.4)‡ (–13.6, 5.6)
LS mean difference from placebo (95% CI) –9.6 –7.5 –8.6 N/A
(–24.1, 4.8) (–21.4, 6.3) (–20.7, 3.5)
*P < 0.05, †P < 0.01, ‡P < 0.001 (analysis of covariance model with treatment group, ALP level [strata] and treatment group by ALP 
level interaction as factors, and baseline value as a covariate). All P values are nominal (not adjusted for multiplicity).
Abbreviation: N/A, not applicable.
taBle 3. (ContinueD)
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minimizing the placebo effect could be the use of a 
more objective surrogate measure of itch, such as the 
biomarker autotaxin, which has been shown to cor-
relate with itch severity and may have some prognos-
tic value.(27) Indeed, in the present study, the observed 
reductions in autotaxin levels with maralixibat and 
the increases with placebo support the improvement 
of pruritus with active treatment. Accounting for the 
placebo effect in clinical trials of cholestatic pruritus 
is difficult. The effect of placebo reported in previ-
ous cholestatic pruritus trials is inconsistent, wors-
ening in one trial and improving in another.(29,30) 
The placebo effect is hypothesized to be mediated 
through dopamine release that occurs in the psycho-
social setting of expectation of reward. Using phar-
maceuticals to inhibit the placebo effect is not yet a 
validated study technique. However, studies involving 
patient-reported outcomes should specifically educate 
investigators/coordinators regarding their interactions 
with patients in order to minimize placebo effects.
Hegade et al.(31) recently published results from a 
small placebo-controlled trial of a different IBAT inhib-
itor for the treatment of pruritus in patients with PBC. 
In that crossover design trial, using a numeric rating 
scale from 0 to 10, the authors reported that pruritus 
improved by 57% in the study drug group and by 23% 
taBle 4. summaRy oF tReatment-emeRgent aes
Patients With AEs, n (%)
Maralixibat
10 mg
(n = 20)
Maralixibat
20 mg
(n = 21)
Maralixibat Overall
(n = 42)
Placebo
(n = 24)
Any AE 19 (95.0) 21 (100.0) 41 (97.6) 17 (70.8)
Any AE potentially related to the drug 15 (75.0) 15 (71.4) 31 (73.8) 11 (45.8)
Maximum severity of AE
Mild 8 (40.0) 5 (23.8) 13 (31.0) 10 (41.7)
Moderate 8 (40.0) 13 (61.9) 22 (52.4) 7 (29.2)
Severe 3 (15.0) 3 (14.3) 6 (14.3) 0 (0.0)
AE leading to study drug discontinuation 1 (5.0) 0 (0.0) 2 (4.8) 0 (0.0)
Serious AE 2 (10.0) 1 (4.8) 3 (7.1) 0 (0.0)
Serious AE potentially related to the drug 1 (5.0) 0 (0.0) 1 (2.4) 0 (0.0)
AE leading to death 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Most common AEs (occurring in ≥10% of patients), number of patients with >1 AE, n (%)
Gastrointestinal disorders 15 (75.0) 18 (85.7) 34 (81.0) 13 (54.2)
Diarrhea 14 (70.0) 11 (52.4) 26 (61.9) 6 (25.0)
Abdominal pain 4 (20.0) 5 (23.8) 10 (23.8) 1 (4.2)
Abdominal pain upper 4 (20.0) 6 (28.6) 10 (23.8) 2 (8.3)
Nausea 5 (25.0) 4 (19.0) 10 (23.8) 4 (16.7)
Abdominal distension 3 (15.0) 0 (0.0) 3 (7.1) 3 (12.5)
General disorders and administration site conditions 4 (20.0) 4 (19.0) 8 (19.0) 2 (8.3)
Chills 2 (10.0) 0 (0.0) 2 (4.8) 0 (0.0)
Musculoskeletal and connective tissue disorders 5 (25.0) 3 (14.3) 8 (19.0) 5 (20.8)
Pain in extremity 0 (0.0) 3 (14.3) 3 (7.1) 0 (0.0)
Back pain 2 (10.0) 0 (0.0) 2 (4.8) 0 (0.0)
Muscle spasms 2 (10.0) 0 (0.0) 2 (4.8) 0 (0.0)
Nervous system disorders 4 (20.0) 3 (14.3) 8 (19.0) 9 (37.5)
Headache 3 (15.0) 2 (9.5) 5 (11.9) 8 (33.3)
Respiratory, thoracic, and mediastinal disorders 7 (35.0) 1 (4.8) 8 (19.0) 1 (4.2)
Cough 4 (20.0) 1 (4.8) 5 (11.9) 0 (0.0)
Skin and subcutaneous tissue disorders 1 (5.0) 2 (9.5) 3 (7.1) 5 (20.8)
Pruritus 0 (0.0) 1 (4.8) 1 (2.4) 3 (12.5)
One patient randomized to receive maralixibat 10 mg was down-titrated to 5 mg owing to tolerability issues. This patient had moderate 
AEs of interest, including diarrhea, abdominal pain, nausea, and vomiting; all AEs were related to the study drug, and one AE of ab-
dominal pain led to study discontinuation. AEs were coded using Medical Dictionary for Regulatory Activities, version 16.0, and 
graded as mild, moderate, or severe in the opinion of the site investigator reporting the AE, using the Common Terminology Criteria 
for AEs, version 4.0.
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in the placebo group. The major differences between 
Hegade et al.’s results and the findings of the present 
study are the percentage improvement in pruritus asso-
ciated with placebo (23% versus 47%, respectively) and 
the duration of the treatment period (2 weeks versus 13 
weeks, respectively). As previously mentioned, the dif-
ference in placebo effect between Hegade et al.’s study 
and the present study could be due to the unwitting 
influence of the two different study teams, but another 
likely factor is the different study designs employed as 
the present study was a parallel group and the Hegade 
et al. study had a crossover with placebo run-in design. 
The placebo run-in may have served to absorb some 
of the placebo effect, assuming the initial optimistic 
expectations of patients are self-limited. Maintaining 
blinding to the study intervention is difficult in a cross-
over design, and unblinding is the antidote to the pla-
cebo effect. The main side effect of IBAT inhibition 
in both studies was gastrointestinal disturbance, and in 
Hegade et al.’s study there were 19 gastrointestinal AEs 
on treatment versus five on placebo. While gastrointes-
tinal disturbance is congruent with the mechanism of 
action and the known effects of excess bile salts in the 
lumen of the colon, such a prominent side effect may 
unblind many patients. With a crossover study design, 
patients receiving a medication with a characteristic side 
effect may readily distinguish between active treatment 
and placebo, and therefore only the treatment period 
before the crossover may be blinded fairly. Analysis of 
only the first treatment arm (before crossover) in the 
Hegade et al. study would also eliminate the potential 
confounder of a therapeutic carryover effect.
Another explanation for the different results 
between the two trials may be the potencies and doses 
of the drugs. In the present study, reductions in sBA 
levels and increases in C4 levels (a measure of de novo 
bile acid synthesis) were observed in the maralixibat 
groups but not in the placebo group. This may indi-
cate that there is some pharmacologic engagement of 
the intended target at the doses used in this study. An 
evaluation of whether such target engagement reached 
a maximum was not possible in this study setting. Of 
note, studies with maralixibat in other patient pop-
ulations found more robust treatment effects with 
no apparent increases in AEs at doses up to 100 mg 
daily. Indeed, separation in findings between active 
treatment and placebo was observed starting at 30 
mg daily dose equivalents. Therefore, higher doses of 
IBAT inhibitors could be investigated in the future 
to increase the effect size, especially given the benign 
safety profile shown in this PBC population.
It was also determined in a post hoc analysis that pro-
portionately more patients with an sBA level >3 times 
ULN at baseline had a treatment response than those 
with an sBA level ≤3 times ULN at baseline. Thus, 
assessing pretreatment sBA levels may help predict which 
patients would respond best to maralixibat. The base-
line sBA level was not reported in ng/mL by Hegade et 
al.(31) However, Hegade et al. reported a greater percent-
age drop in sBA levels compared with the present study, 
which could be due to differences in either drug potency 
or baseline sBA levels in the two populations studied.
In the present study, gastrointestinal AEs in the 
maralixibat groups were reported in proportionately 
fewer patients during the stable dosing period than 
during the dose-escalation period (weeks 2-4 after 
treatment initiation), suggesting that gastrointestinal 
AEs may attenuate with increased duration of IBAT 
inhibition. Slower dose escalation could potentially be 
used as a strategy to administer higher doses with better 
gastrointestinal tolerance and potentially higher efficacy.
In conclusion, maralixibat was not associated 
with statistically significant improvements in pru-
ritus in patients with PBC compared with placebo. 
However, the placebo effect observed in this study 
was large enough (47%) to mask the expected effect 
of an IBAT inhibitor. This fortuitously named 
CLARITY trial has led to a clearer vision of how 
future trials of drugs that inhibit bile acid reabsorp-
tion to treat cholestatic pruritus should be carefully 
designed to minimize the placebo effect as well 
as gastrointestinal side effects. Study design, dose 
range, dosing scheme, and patient selection are all 
important factors that should be carefully consid-
ered in future trials.
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